<DOC>
	<DOCNO>NCT02535975</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , placebo-controlled study effect metformin patient mild Graves ' ophthalmopathy . Eighty patient mild ophthalmopathy include . Each patient give either metformin ( 500mg PO three time day ) placebo ( PO three time day ) 6 month follow 6 month withdrawal treatment .</brief_summary>
	<brief_title>The Effects Metformin Patients With Mild Graves ' Ophthalmopathy</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Age 1880 year 2 . Patients diabetes ( HbA1c level screen low 6.5 ) 3 . Mild Graves ' ophthalmopathy accord EUGOGO statement . 4 . Clinical activity score low 4 5 . Being euthyroid least 2 month enrollment 6 . No previous specific therapy GO 6 month enrollment except local measure ( e.g . eye drop ) 1 . Moderatesevere Graves ' ophthalmopathy 2 . Clinical activity score â‰¥ 4 3 . Contraindication metformin use follow : renal dysfunction ( creatinine level within normal range ) , liver dysfunction ( AST ALT level within normal range ) , severe concomitant illness 4 . Pregnant woman 5 . Current use metformin contain preparation 6 . Metformin intolerance 7 . Inability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>